Search

Background: The mortality rate from breast cancer has declined in recent years. The combination of cyclophosphamide, methotrexate, and 5-fluorouracil, as a pioneer adjuvant chemotherapy for breast cancer, followed by the introduction of anthracycline/taxane-based regimens have resulted in favorable outcomes for early-stage breast cancer. The current study aimed to compare breast cancer treatment outcomes between the cyclophosphamide, methotrexate, and 5-fluorouracil and anthracycline/taxane-based regimens. Methods: In this cohort study, we extracted medical records of 1098 breast cancer patients who referred to oncology centers affiliated with Mashhad University of Medical Sciences from 1991 to 2011. We included patients with Stages I and II invasive cancers who were candidates for systemic chemotherapy. Patients were divided into the cyclophosphamide, methotrexate, and 5-fluorouracil or anthracycline/taxane-based arms. We considered median event-free survival, median overall survival, 5- and 10-year event-free survival, and 5- and 10-year overall survival as the study endpoints. Results: The cyclophosphamide, methotrexate, and 5-fluorouracil arm had a median event-free survival of 190 months, with a 5-year event-free survival of 77% and 10-year event-free survival of 61%. The anthracycline/taxane arm had a median event-free survival of 212 months, a 5-year event-free survival of 74%, and a 10-year event-free survival of

Background: This study assesses the effect of oral cryotherapy on the incidence and severity of chemotherapy-induced oral mucositis in combined chemotherapy regimens.Methods: This was a randomized controlled trial that enrolled 80 cancer patients. We evaluated the primary oral status of all patients prior to chemotherapy. Patients were divided into two groups, experimental and control. The experimental group was given ice to place in their mouths from 5 min before to 5 min after chemotherapy.The control group received no intervention. Both groups were treated with the following chemotherapy regimens: i) 5- fluorouracil + leucovorin; ii) cyclophosphamide + adriamycin + 5-fluorouracil; or iii) cyclophosphamide + methotrexate + fluorouracil. World Health Organization and patient-based oral mucositis scales were used for evaluation.Results: According to the WHO based Oral Mucositis Scale, the incidence of oral mucositis in the intervention group (45%) was significantly lower than the control group (77.5%; P=0.01). The incidence of oral mucositis in the intervention group based on the Patient-Judged Oral Mucositis Scale was lower than the control group. The findings of this study indicated that patients who underwent cryotherapy had less severe oral mucositis based on both WHO (P=0.01) and patient oral mucositis scales (P=0.001).Conclusion: Oral cryotherapy because of its ease of application, tolerability and lack of side effects makes it an important resource for reducing the incidence and severity of oral mucositis. The role of oncology nurses is crucial to the application and success of oral cryotherapy.